Treatment of glioblastoma in Greenlandic patients
ABSTRACTGlioblastoma (GBM), WHO grade IV, is the most common primary malignant brain tumour among adults with a devastating overall survival of 14–22 months. Standard treatment of GBM includes maximum safe resection, radiotherapy plus concomitant and adjuvant temozolomide (TMZ), given over a period...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | International Journal of Circumpolar Health |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22423982.2023.2285077 |
| _version_ | 1797385597911826432 |
|---|---|
| author | Simone Frandsen Alice Juhl Pedersen Ole Gredal Søren Møller Uka Wilhjelm Geissler Dorte Schou Nørøxe |
| author_facet | Simone Frandsen Alice Juhl Pedersen Ole Gredal Søren Møller Uka Wilhjelm Geissler Dorte Schou Nørøxe |
| author_sort | Simone Frandsen |
| collection | DOAJ |
| description | ABSTRACTGlioblastoma (GBM), WHO grade IV, is the most common primary malignant brain tumour among adults with a devastating overall survival of 14–22 months. Standard treatment of GBM includes maximum safe resection, radiotherapy plus concomitant and adjuvant temozolomide (TMZ), given over a period of approximately 9 months. Treatment and follow-up for Greenlandic patients with GBM are managed at Rigshospitalet (RH), Copenhagen. Greenlandic GBM patients, therefore, travel back and forth to RH, often unaccompanied, and challenged by cognitive failure or other symptoms from their disease and/or treatment. Few Greenlandic patients are diagnosed with GBM annually, but considering the poor prognosis and short remaining lifespan, it would be preferable to limit their travels. TMZ is administrated as capsules. Health personnel at Queen Ingrid’s Hospital (DIH), Nuuk, are trained in treating other oncological diseases and handling side effects. Hence, it could be investigated whether administration of adjuvant TMZ at DIH could be feasible after personnel education as well as economic consideration and compensation, in close collaboration with neuro oncologists at RH. In this article, we describe the Greenlandic cancer treatment, and the typical workflow from diagnosis of GBM to treatment to progression. |
| first_indexed | 2024-03-08T21:56:28Z |
| format | Article |
| id | doaj.art-e4a1520eaa1747a3a180ecf3576ad7c6 |
| institution | Directory Open Access Journal |
| issn | 2242-3982 |
| language | English |
| last_indexed | 2024-03-08T21:56:28Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | International Journal of Circumpolar Health |
| spelling | doaj.art-e4a1520eaa1747a3a180ecf3576ad7c62023-12-19T21:44:11ZengTaylor & Francis GroupInternational Journal of Circumpolar Health2242-39822023-12-0182110.1080/22423982.2023.2285077Treatment of glioblastoma in Greenlandic patientsSimone Frandsen0Alice Juhl Pedersen1Ole Gredal2Søren Møller3Uka Wilhjelm Geissler4Dorte Schou Nørøxe5Department of Medicine, Queen Ingrid’s Hospital, Nuuk, GreenlandDepartment of Medicine, Queen Ingrid’s Hospital, Nuuk, GreenlandDepartment of Medicine, Queen Ingrid’s Hospital, Nuuk, GreenlandDepartment of Oncology, Copenhagen University Hospital, Copenhagen, DenmarkDepartment of Medicine, Queen Ingrid’s Hospital, Nuuk, GreenlandDepartment of Medicine, Queen Ingrid’s Hospital, Nuuk, GreenlandABSTRACTGlioblastoma (GBM), WHO grade IV, is the most common primary malignant brain tumour among adults with a devastating overall survival of 14–22 months. Standard treatment of GBM includes maximum safe resection, radiotherapy plus concomitant and adjuvant temozolomide (TMZ), given over a period of approximately 9 months. Treatment and follow-up for Greenlandic patients with GBM are managed at Rigshospitalet (RH), Copenhagen. Greenlandic GBM patients, therefore, travel back and forth to RH, often unaccompanied, and challenged by cognitive failure or other symptoms from their disease and/or treatment. Few Greenlandic patients are diagnosed with GBM annually, but considering the poor prognosis and short remaining lifespan, it would be preferable to limit their travels. TMZ is administrated as capsules. Health personnel at Queen Ingrid’s Hospital (DIH), Nuuk, are trained in treating other oncological diseases and handling side effects. Hence, it could be investigated whether administration of adjuvant TMZ at DIH could be feasible after personnel education as well as economic consideration and compensation, in close collaboration with neuro oncologists at RH. In this article, we describe the Greenlandic cancer treatment, and the typical workflow from diagnosis of GBM to treatment to progression.https://www.tandfonline.com/doi/10.1080/22423982.2023.2285077GlioblastomaGreenlandInuitbrain cancertemozolomideradiotherapy |
| spellingShingle | Simone Frandsen Alice Juhl Pedersen Ole Gredal Søren Møller Uka Wilhjelm Geissler Dorte Schou Nørøxe Treatment of glioblastoma in Greenlandic patients International Journal of Circumpolar Health Glioblastoma Greenland Inuit brain cancer temozolomide radiotherapy |
| title | Treatment of glioblastoma in Greenlandic patients |
| title_full | Treatment of glioblastoma in Greenlandic patients |
| title_fullStr | Treatment of glioblastoma in Greenlandic patients |
| title_full_unstemmed | Treatment of glioblastoma in Greenlandic patients |
| title_short | Treatment of glioblastoma in Greenlandic patients |
| title_sort | treatment of glioblastoma in greenlandic patients |
| topic | Glioblastoma Greenland Inuit brain cancer temozolomide radiotherapy |
| url | https://www.tandfonline.com/doi/10.1080/22423982.2023.2285077 |
| work_keys_str_mv | AT simonefrandsen treatmentofglioblastomaingreenlandicpatients AT alicejuhlpedersen treatmentofglioblastomaingreenlandicpatients AT olegredal treatmentofglioblastomaingreenlandicpatients AT sørenmøller treatmentofglioblastomaingreenlandicpatients AT ukawilhjelmgeissler treatmentofglioblastomaingreenlandicpatients AT dorteschounørøxe treatmentofglioblastomaingreenlandicpatients |